Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study [Corrigendum]

Abstract

Restelli U, Ceresoli GL, Croce D et al. Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study. Cancer Management and Research. 2017;9:789–800.On page 796, above the Disclosure section, the Acknowledgment section is missing. The missing text is:AcknowledgmentThe authors thank Ray Hill, an independent medical writer, who provided English-language editing and journal styling prior to submission on behalf of Health Publishing & Services Srl. Editorial support was funded through an unconditional contribution by Bayer SpA.Read the original article.